The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study alternating mFOLFOX 6 and FOLFIRI (FIREFOX) plus bevacizumab (bev) regimen in first-line treatment of advanced colorectal cancer in Japanese patients (KSCC 0801).
Yutaka Ogata
No relevant relationships to disclose
Yoshito Akagi
No relevant relationships to disclose
Yoshihiro Kakeji
Honoraria - Chugai Pharma
Yasunori Emi
No relevant relationships to disclose
Eiji Oki
No relevant relationships to disclose
Hiroshi Saeki
No relevant relationships to disclose
Tetsuo Touyama
No relevant relationships to disclose
Hironori Samura
No relevant relationships to disclose
Hideo Baba
No relevant relationships to disclose
Shoji Natsugoe
No relevant relationships to disclose
Kazuo Shirouzu
No relevant relationships to disclose
Shoji Tokunaga
No relevant relationships to disclose
Yoshihiko Maehara
Research Funding - Chugai Pharma; Yakult